


# INPHOG Newsletter

2023, Vol 9, Issue 1


Dear INPHOG Delegates,

It gives us immense pleasure to bring you the latest edition of the INPHOG Newsletter. Since our last newsletter just under 9 months ago, there has been sustained progress in many areas and these newsletters are invaluable in communicating all the information in detail and for the record which you can look at as per your convenience.


The first significant progress has been in the increase in the number of **MEMBER INSTITUTIONS** to 43 as shown in the map below



The distribution of these centers is as shown in the pie charts below



In parallel, there is a growing number of **DELEGATES** who are all individuals (from member or non-member institutions). Today we have 231 delegates which includes 157 delegates from the 43 INPHOG member institutions and 74 delegates from 61 non-member institutions. These delegates belong to the following specialties as shown in the pie chart below



Another major development has been the nomination of new **SUBCOMMITTEE CHAIRS**. This had been held in abeyance during the pandemic and subsequently till the transition of InPOG to INPHOG Research Foundation was complete. Please find the details in the Table below. Also, a new subcommittee on **CELL AND GENE THERAPY** led by Dr Gaurav Narula has been added.

S No	Subcommittee	New chair
1	Acute Lymphoblastic Leukemia	Dr Venkatraman Radhakrishnan
2	Acute Myeloid Leukemia	Dr Smita Kayal
3	Chronic Myeloproliferative Disorders	Dr Aditya Gupta
4	Hodgkin's Lymphoma	Dr Payal Malhotra
5	Non-Hodgkin Lymphoma	Dr Nirmalaya Moulik
6	Histiocytosis	Dr Ramya Uppuluri
7	Central Nervous System Tumours	Dr Vikramjit Kanwar
8	Neuroblastoma	Dr Yamini Krishnan
9	Retinoblastoma	Dr Amita Mahajan
10	Wilms Tumour	Dr Shalini Mishra
11	Liver Tumours	Dr Vimal Kumar
12	PNET	Dr Vasudev Bhat
13	Osteosarcoma	Dr Akshay Tiwari
14	Soft Tissue Sarcoma	Dr Reghu KS
15	Germ Cell Tumours	Dr Sonali Mohapatra
16	Rare & Epithelial Tumour	Dr Aruna Rajendran
17	Cell & Gene Therapy	Dr Gaurav Narula
18	Hematopoietic Stem Cell Transplant	Dr Ponni Sivaprakasan
19	Access to Care	Dr Shruti Kakkar
20	Supportive Care	Dr Gargi Das
21	Epidemiology	Dr Ramandeep Arora
22	Surv & Late Eff	Dr Rachna Seth
23	Palliative Care	Dr Veronique Dinand
24	Cancer Genetics	Dr Badira CP
25	Hemoglobinopathy & /RBC Disorders	Dr Bhavna Dhingra
26	Platelet & Coagulation Disorders	Dr Vandana Bhardwaj
27	Bone Marrow Failure	Dr Mukul Agarwal

Finally, and perhaps most importantly the funds which we have received from the SIOP PARC grant, the Srinivas Cankids APML fund, and a few other sources has allowed us to recruit the first Clinical Research Coordinators. Please meet our staff who are present in centers across the country.



**Tanya Dhawan**  
INPHOG Delhi



**Leya George**  
JIPMER, P'cherry



**Divya Pratihast**  
RGCI, New Delhi



**Sarthak Sahu**  
TMC, Kolkata



**Akshita Yadav**  
KGMU, Lucknow



**Priya Saxena**  
APOLLO, Delhi



**Aditya Gaikwad**  
BJ WADIA, Mumbai



**Shikha Kumari**  
AIIMS, Delhi



**Nichila Mary Philip**  
ADYAR, Chennai

As always, we welcome suggestions and feedback and would request that you send them to [admin@inphog.org](mailto:admin@inphog.org)

Warm wishes  
INPHOG

## Study Summary Portfolio (Total 32)

Subcommittee	Provisional Registration (3)	Full Registration (1)	Recruitment Ongoing (12)	Recruitment Complete (16)
ALL			InPOG-ALL-19-02	InPOG-ALL-15-01
AML			INPHOG-AML-23-02	InPOG-AML-16-01
Ch Myelop Dis				InPOG-CML-16-01
HL			InPOG-HL-19-03	InPOG-HL-15-01 InPOG-HL-17-02
NHL				InPOG-NHL-16-01
Histiocytosis			InPOG-HIST-19-03	InPOG-HIST-17-01
CNS				
Neuroblastoma		InPOG-NB-18-02		InPOG-NB-18-01
Retinoblastoma			InPOG-RB-17-01	
Renal				InPOG-WT-18-02
Liver				
Osteosarcoma				
PNET			InPOG-PNET-19-02	InPOG-PNET-16-01
Soft Tissue Sarcoma				
Germ Cell Tumours			INPHOG-GCT-22-01	
Rare, Epithelial			InPOG-RARE-17-02 InPOG-RARE-17-01	
HSCT	InPOG-SCT-20-02			
Access to Care				InPOG-ACC-16-01 InPOG-ACC-16-02 InPOG-ACC-16-03 InPOG-ACC-20-04
Supportive Care	INPHOG-SUPP-23-04		INPHOG-SUPP-22-03	
Epidemiology			InPOG-EPI-20-02	InPHOG-EPI-22-03
Late Effects			InPOG-LE-16-01	
Palliative Care				InPOG-PALL-18-01
Cancer Genetics				
Hbpathy/RBC	INPHOG-RBC-22-01			
Plat & Coag				
BM Failure				

# INPHOG Studies - Recruitment Complete (16)

---

## InPOG-HL-15-01

**A collaborative study for newly diagnosed childhood Hodgkin's lymphoma patients in India**

<b>Principal Investigator</b>	Prof Jagdish Chandra
<b>Registered with INPHOG</b>	June 2015
<b>CTRI Registration</b>	CTRI/2016/03/010916
<b>Patients recruited</b>	410
<b>Recruitment Closed</b>	February 2018
<b>Centers study open in</b>	27 centers

## Publications

- Arora RS, Mahajan A, Dinand V, Kalra M, Jain S, Taluja A, Mandal P, Chandra J. InPOG-HL-15-01 - Challenges and Lessons Learnt in Setting up the First Collaborative Multicentre Prospective Clinical Trial in Childhood Cancer in India. *Pediatric Hematology Oncology J* 2020. Oct 1;5(4):166-70.
- Mahajan A, Singh M, Bakhshi S, Jain S, Seth R, Verma N, Kumar A, Radhakrishnan V, Mandal P, Kapoor G, Arora RS, Dinand V, Kalra M, Sharma A, Phulkar S, Arora A, Chandra J. Treating Early-Stage Hodgkin Lymphoma in resource limited settings: InPOG-HL-15-01 Experience. *Pediatric Blood & Cancer*. 2021 Jul 22:e29219.
- Jain S, Bakhshi S, Seth R, Verma N, Singh M, Mahajan A, Radhakrishnan V, Mandal P, Arora RS, Dinand V, Kalra M, Sharma A, Chandra J. Risk based and response adapted radiation therapy for children and adolescents with newly diagnosed advanced Hodgkin lymphoma treated with ABVD chemotherapy: A report from the Indian Pediatric Oncology Group study InPOG-HL-15-01. *Leuk Lymphoma* 2021 Dec 9:1-8
- Mahajan A, Bakhshi S, Singh M, Seth R, Verma N, Jain S, Radhakrishnan V, Mandal P, Arora RS, Dinand V, Kalra M, Kapoor G, Sajid M, Kumar R, Mallick S, Taluja A, Chandra J. Empirical antitubercular treatment for lymphadenopathy: Are we missing lymphoma? *Indian J Pediatr*. 2022 Jun 23.
- Mahajan A, Bakhshi S, Seth R, Verma N, Mandal P, Singh M, Jain S, Radhakrishnan V, Kanvinde S, Arora RS, Dinand V, Kalra M, Taluja A, Mallick S, Kumar R, Chandra J. Hodgkin lymphoma in children under 5 years: Do they behave differently? *J Pediatr Hematol Oncol*. 2022 May 1;44(4):186-190.
- Kalra M, Bakshi S, Singh M, Seth R, Verma N, Jain S, Radhakrishnan V, Mandal P, Mahajan A, Arora RS, Dinand V, Kapoor G, Sajid M, Kumar R, Taluja A, Mallick S, Chandra J. Response assessment with Positron Emission Tomography-Computed tomography as compared with contrast enhanced computed tomography in Childhood Hodgkin Lymphoma can reduce the need for radiotherapy in low- and middle-income countries. *Pediatr Blood cancer* 2022; e 30091. – **NEW**

## InPOG NHL-16-01

**A Retrospective Multi-Centric Study of Contemporary Epidemiology & Outcome of Childhood B-NHL in India**

<b>Principal Investigator</b>	Dr Amita Trehan
<b>Registered with INPHOG</b>	October 2016
<b>CTRI Registration</b>	No
<b>Patients recruited</b>	323

**Recruitment Closed** April 2018  
**Centers study open in** 09 centers

### Publications

- Rahiman EA, Bakhshi S, Deepam Pushpam, Ramamoorthy J, Das A, Ghara N, Kalra M, Kapoor G, Meena JP, Siddaigarhi S, Thulkar S, Sharma MC, Srinivasan R, Trehan A. Outcome and prognostic factors in childhood B non-Hodgkin lymphoma from India: Report by the Indian Pediatric Oncology Group (InPOG-NHL-16-01 study). *Pediatr Hematol Oncol.* 2022 Jan 3:1-15.

#### **InPOG-ACC-16-01**

#### **Multi-site Prospective Study to Determine Household Out-of-Pocket Expenditure Incurred by Families of Children Newly Diagnosed with Cancer in India (HOPE Study)**

**Principal Investigator** Dr Ramandeep Singh Arora  
**Registered with INPHOG** August 2016  
**CTRI Registration** CTRI/2016/11/007492  
**Patients recruited** 402  
**Recruitment Closed** November 2017  
**Centers study open in** 15 centers

#### **InPOG-ACC-16-03**

#### **Exploring Barriers and Enablers to Accessing Care for Childhood Cancers in India: A Multi-center Qualitative Study**

**Principal Investigator** Dr Ramandeep Singh Arora  
**Registered with INPHOG** May 2017  
**CTRI Registration** No  
**Patients recruited** 34 patients + 27 healthcare providers  
**Recruitment Closed** January 2018  
**Centers study open in** 7 centers

### Publications

- Faruqui N, Joshi R, Martiniuk A, Lowe J, Arora R, Anis H, Kalra M, Bakhshi S, Mishra A, Santa A, Sinha S, Siddaiahgari S, Seth R, Bernays S. A health care labyrinth: perspectives of caregivers on the journey to accessing timely cancer diagnosis and treatment for children in India. *BMC Public Health.* 2019 Dec 2;19(1):1613.
- Faruqui N, Bernays S, Martiniuk A, Abimbola S, Arora R, Lowe J, Denburg A, Joshi R, Access to care for childhood cancers in India: perspectives of health care providers and the implications for Universal Health Coverage. *BMC Public Health* 2020 Dec;20(1):1-1.



### **InPOG-PNET-16-01**

#### **Evaluation of clinicopathological characteristics, prognostic factors and treatment outcomes in patients with PNET of Kidney: An InPOG study**

<b>Principal Investigator</b>	Dr Bivas Biswas
<b>Registered with INPHOG</b>	June 2016
<b>CTRI Registration</b>	No
<b>Patients recruited</b>	40
<b>Recruitment Closed</b>	August 2018
<b>Centers study open in</b>	2 centers

### **InPOG-CML-16-01**

#### **Study of treatment and outcome of chronic myeloid leukemia in children and adolescents in India**

<b>Principal Investigator</b>	Prof Deepak Bansal
<b>Registered with INPHOG</b>	Feb 2018
<b>CTRI Registration</b>	No
<b>Patients recruited</b>	171
<b>Recruitment Closed</b>	January 2019
<b>Centers study open in</b>	9 centers

### **InPOG-AML-16-01**

#### **Randomized Phase III Study Comparing DA (3+7) Versus ADE as Induction Chemotherapy in children with Acute Myeloid Leukemia**

<b>Principal Investigator</b>	Dr Venkatraman Radhakrishnan
<b>Registered with INPHOG</b>	April 2016
<b>CTRI Registration</b>	CTRI/2014/11/005202
<b>Patients recruited</b>	150
<b>Recruitment Closed</b>	Nov 2019
<b>Centers study open in</b>	5 centers

### **Publications**

- Radhakrishnan V, Bakhshi S, Kayal S, Thampy C, Batra A, Shenoy PK, Kumar H, Rajaraman S, Chaudhary S, Bisht R, Dubashi B, Ganesan TS. Two-drug versus three-drug induction chemotherapy in pediatric acute myeloid leukemia: a randomized controlled trial. Blood Cancer J. 2022 Sep 6;12(9):131. doi: 10.1038/s41408-022-00726-1. Erratum in: Blood Cancer J. 2022 Sep 27;12(9):139. PMID: 36068213; PMCID: PMC9444698.

**InPOG-HIST-17-01**

**Indian Hemophagocytic Lymphohistiocytosis Registry (I-HLH): Establishment of a nationwide prospective web-based registry for patients diagnosed with HLH**

<b>Principal Investigator</b>	Dr Mukesh Desai
<b>Registered with INPHOG</b>	July 2017
<b>CTRI Registration</b>	Not done
<b>Patients recruited</b>	20
<b>Recruitment Closed</b>	Feb 2021
<b>Centers study open in</b>	8 centers

**InPOG-ACC-16-02**

**Accessing Childhood CancEr Services in INDIA (ACCESS INDIA)**

<b>Principal Investigator</b>	Dr Ramandeep Singh Arora
<b>Registered with INPHOG</b>	Sep 2018
<b>CTRI Registration</b>	Not done
<b>Patients recruited</b>	2850
<b>Recruitment Closed</b>	Feb 2021
<b>Centers study open in</b>	71 centers

**InPOG-ACC-20-04**

**The impact of COVID-19 pandemic on care of children with cancer in India**

<b>Principal Investigator</b>	Dr Ramandeep Arora
<b>Registered with INPHOG</b>	May 2020
<b>CTRI Registration</b>	CTRI/2020/05/025219
<b>Patients recruited</b>	1146
<b>Recruitment Closed</b>	Feb 2021
<b>Centers study open in</b>	30 centers

**Publications**

- Sharma J, Mahajan A, Bakhshi S, Patil V, Verma N, Radhakrishnan V, Singh A, Kayal S, Seth R, Pushpam D, Arora RS. The impact of COVID-19 pandemic on access to treatment for children with cancer in India and treating center practices. Cancer. 2022 Feb 1;128(3),579-86.

### **InPOG-ALL-15-01**

#### **An Indian Childhood Collaborative Leukemia Group multicentre national standardization study for newly diagnosed acute lymphoblastic leukemia**

<b>Principal Investigator</b>	Prof Vaskar Saha
<b>Registered with INPHOG</b>	July 2015
<b>CTRI Registration</b>	CTRI/2015/12/006434
<b>Patients recruited</b>	2516
<b>Recruitment Closed</b>	Aug 2022
<b>Centers study open in</b>	5 centers

### **Publications**

- Das N, Banavali S, Bakhshi S, Trehan A, Radhakrishnan V, Seth R, Arora B, Narula G, Sinha S, Roy P, Gogoi MP, Chatterjee S, Abraham B, Das P, Saha V, Krishnan S. Protocol for ICiCle-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India. *Trials*. 2022 Jan 31;23(1):102.

### **InPOG-HL-17-02**

#### **Prospective Collaborative Study for Relapsed/Refractory Hodgkin Lymphoma**

<b>Principal Investigator</b>	Dr Amita Mahajan
<b>Registered with INPHOG</b>	May 2018
<b>CTRI Registration</b>	Ref/2019/03/024719
<b>Patients recruited</b>	45
<b>Recruitment Closed</b>	SEP 2023
<b>Centers study open in</b>	13 centers

### **InPOG-NB-18-01**

#### **India Neuroblastoma Registration and Biology Study**

<b>Principal Investigator</b>	Dr Vikramjit Kanwar
<b>Registered with INPHOG</b>	Nov 2018
<b>CTRI Registration</b>	CTRI/2020/01/023088
<b>Patients recruited</b>	311
<b>Recruitment Closed</b>	SEP 2023
<b>Centers study open in</b>	14 centers

**InPOG-EPI-20-02**  
**Indian COVID-19 Childhood Cancer Registry**

<b>Principal Investigator</b>	Dr Revathi Raj
<b>Registered with INPHOG</b>	May 2020
<b>CTRI Registration</b>	CTRI/2020/05/025221
<b>Patients recruited</b>	659
<b>Recruitment Closed</b>	JUL 2023
<b>Centers study open in</b>	37 centers

**Publications**

- Raj R, Uppuluri R, Parambil B, Dhariwal N, Totadri S, Mathew LG, Radhakrishnan V, Charan A, Yadav SP, Mahajan A, Mudaliar S. Outcomes of COVID-19 in children with cancer—Report from the Indian Pediatric Oncology Group (InPOG) COVID-19 registry in India. Pediatric Hematology Oncology Journal. 2022 Jun 1;7(2):34-7.

**InPOG-PALL-18-01**

**Patterns of End-Of-Life Care in Children with Cancer in India – A Multicentre Retrospective Study**

<b>Principal Investigator</b>	Dr Gayatri Palat
<b>Registered with INPHOG</b>	Sep 2020
<b>CTRI Registration</b>	CTRI/2020/12/029960
<b>Patients recruited</b>	384
<b>Recruitment Closed</b>	JUL 2023
<b>Centers study open in</b>	17 centers

**InPOG-WT-18-02**

**Pattern of care and survival of renal tumors in children in India - Multi center study**

<b>Principal Investigator</b>	Dr Sirisharani Siddaiahgari
<b>Registered with INPHOG</b>	Apr 2020
<b>CTRI Registration</b>	CTRI/2021/01/030770
<b>Patients recruited</b>	443
<b>Recruitment Closed</b>	JUL 2023
<b>Centers study open in</b>	17 centers

# INPHOG Studies - Recruitment Ongoing (12)

---

## InPOG-LE-16-01

**The Indian Childhood Cancer Survivorship Study (C2S study): After treatment completion registry of childhood cancers – Phase 1**

<b>Principal Investigator</b>	Dr Rachna Seth
<b>Registered with INPHOG</b>	May 2016
<b>CTRI Registration</b>	Not done
<b>Recruitment commenced</b>	June 2016
<b>Currently patients recruited</b>	2534
<b>Target patient recruitment</b>	At least 500 (desirable 1000)
<b>Anticipated duration of recruitment</b>	5 years (Project extended till 2025)
<b>Centers study open in</b>	18 centers

- All India Institute of Medical Sciences, New Delhi
- Apollo Hospital, Chennai
- Banaras Hindu University, Varanasi
- Cancer Institute, Chennai
- Indraprastha Apollo Hospital, New Delhi
- Kalawati Children’s Hospital, New Delhi
- Kidwai Memorial Institute, Bangalore
- King George’s medical University, Lucknow
- Max Super Specialty Hospital, Patparganj, New Delhi
- Max Super Specialty Hospital, Saket, New Delhi
- Rainbow Children’s Hospital, Hyderabad
- Rajiv Gandhi Cancer Institute, New Delhi
- Regional Cancer Centre, Thiruvananthapuram
- Safdarjung Hospital, New Delhi
- SION Hospital, Mumbai
- Tata Medical Centre, Kolkata
- Tata Memorial Hospital, Mumbai
- AIIMS, Jodhpur - **NEW**

## InPOG-RARE-17-02

**Indian Childhood Advanced Nasopharyngeal Carcinoma Study (ICANaPS)**

**A multicenter, prospective, pilot study on use of platinum-based chemotherapy for pediatric nasopharyngeal carcinoma and exploration of the role of plasma Epstein-Barr virus (EBV)-DNA PCR titers in predicting relapse**

<b>Principal Investigator</b>	Dr Reghu
<b>Registered with INPHOG</b>	October 2018
<b>CTRI Registration</b>	
<b>Recruitment commenced</b>	Yes
<b>Currently patients recruited</b>	2
<b>Target patient recruitment</b>	50
<b>Anticipated duration of recruitment</b>	5 years
<b>Centers study open in</b>	1

- Tata Medical Centre, Kolkata

#### **InPOG-RARE-17-01**

### **Clinical Course, Pathological Spectrum and Outcomes in Paediatric Rare Tumours in India: A Multicentric Observational Study**

<b>Principal Investigator</b>	Dr Maya Prasad
<b>Registered with INPHOG</b>	July 2017
<b>CTRI Registration</b>	CTRI/2019/02/017851
<b>Recruitment commenced</b>	Yes
<b>Currently patients recruited</b>	215
<b>Target patient recruitment</b>	250
<b>Anticipated duration of recruitment</b>	5 years
<b>Centers study open in</b>	10

- All India Institute of Medical Sciences, New Delhi
- Apollo hospital, Chennai
- BJ Wadia Hospital, Mumbai
- Cancer Institute, Chennai
- Indraprastha Apollo Hospital, New Delhi
- Kasturba Medical College, Mangalore
- King George's medical University, Lucknow
- Rainbow Children's Hospital, Hyderabad
- Tata Medical Centre, Kolkata
- Tata Medical Centre, Mumbai

#### **InPOG-ALL-19-02**

### **Registry study for relapsed childhood acute lymphoblastic leukaemia using protocol ALL-R1.**

<b>Principal Investigator</b>	Vaskar Saha
<b>Registered with INPHOG</b>	Jun 2019

<b>CTRI Registration</b>	CTRI/2019/10/021758
<b>Recruitment commenced</b>	Yes
<b>Currently patients recruited</b>	51
<b>Target patient recruitment</b>	220
<b>Anticipated duration of recruitment</b>	5 years
<b>Centers study open in</b>	1

- Tata Medical Centre, Kolkata

### **InPOG-HIST-19-03**

#### **Prospective Collaborative Study for pulse dexamethasone and lenalidomide in Relapsed / Refractory Langerhans cell histiocytosis (LENDEX-LCH study)**

<b>Principal Investigator</b>	Dr Ramya Uppuluri
<b>Registered with INPHOG</b>	Aug 2019
<b>CTRI Registration</b>	CTRI/2020/07/026937
<b>Recruitment commenced</b>	Yes
<b>Currently patients recruited</b>	12
<b>Target patient recruitment</b>	50
<b>Anticipated duration of recruitment</b>	3 years
<b>Centers study open in</b>	10

- All India Institute of Medical Sciences, New Delhi
- Apollo Hospital, Chennai
- Indraprastha Apollo Hospital, New Delhi
- Kauvery Hospital, Trichy
- Post graduate institute of Child health Noida
- Rainbow Children's Hospital, Hyderabad
- Sri Aurobindo Institute of Medical Sciences, Indore
- Sri Ramachandra Institute of Higher Education and Research, Chennai
- Tata Medical Centre, Kolkata
- Tata Memorial Hospital, Mumbai

### **InPOG-RB-17-01**

#### **A Prospective Collaborative Study for Newly Diagnosed patients with Retinoblastoma**

<b>Principal Investigator</b>	Dr Santosh Honavar
<b>Registered with INPHOG</b>	Sep 2019
<b>CTRI Registration</b>	CTRI/2020/09/027846
<b>Recruitment commenced</b>	Yes
<b>Currently patients recruited</b>	797

**Target patient recruitment** 1066  
**Anticipated duration of recruitment** 3 years  
**Centers study open in** 20

- AIIMS, New Delhi
- Aravind Hospital, Coimbatore
- BHU, Department of Pediatrics
- Center for sight, Hyderabad
- GMCH Chandigarh
- HV Desai eye Hospital Pune
- Indra Gandhi Institute of Medical Sciences, Patna
- KGMU Lucknow
- LVPI Bhuvneshwar
- MGM Eye Institute, Raipur
- MVR Cancer Center & Research Institute, Calicut
- NH Bangalore
- PGI Chandigarh
- RIO MCK Hospital Kolkata
- Sankara Eye Hospital, Bangalore
- Shroff's Charity Eye Hospital, New Delhi
- SMS Hospital, Jaipur
- SRCC Mumbai
- Sri Sankaradeva Nethrayala Hospital, Guwahati
- Susrut Eye Foundation & Research Centre. Kolkata

**InPOG-HL-19-03**

**Response-Adapted Management of Childhood Classical Hodgkin Lymphoma (cHL) and Early Response Assessment by Positron Emission and Computerized Tomography (PET-CT) to allow Omission of Radiotherapy in Indian Children with Treated with a Standard of Care Intensified Chemotherapy Regimen.**

**Principal Investigator** Dr Gaurav Narula  
**Registered with INPHOG** Feb 2020  
**CTRI Registration** CTRI/2020/08/027495  
**Recruitment commenced** Yes  
**Currently patients recruited** 178  
**Target patient recruitment** 700  
**Anticipated duration of recruitment** 5 years  
**Centers study open in** 8

- Bai Jerabai Wadia Hospital, Mumbai
- Homi Bhabha Cancer Hospital, Varanasi



- Indraprastha Apollo Hospital, Delhi
- Kasturba Medical College, Manipal
- Rajiv Gandhi Cancer Institute & Research center, Delhi
- Tata Memorial Hospital, Mumbai
- Apollo Cancer Centre, Chennai- **NEW**
- Cancer Institute (W.I.A) Adyar, Chennai- **NEW**

### InPOG-PNET-19-02

**Evaluation of clinic-pathological characteristics, prognostic factors and treatment outcomes in patients with ESFT in children and young adults.**

<b>Principal Investigator</b>	Dr Sandeep Jain
<b>Registered with INPHOG</b>	May 2021
<b>CTRI Registration</b>	Applied for
<b>Recruitment commenced</b>	Yes
<b>Currently patients recruited</b>	1200
<b>Target patient recruitment</b>	1000
<b>Anticipated duration of recruitment</b>	Not applicable - Retrospective
<b>Centers study open in</b>	09

- Indraprastha Apollo Hospital, New Delhi
- Max Super Specialty Hospital, Saket, New Delhi
- Rajiv Gandhi Cancer Institute, New Delhi
- MVR Cancer Centre, Kozhikode
- Tata Memorial Hospital, Mumbai
- KGMU, Lucknow
- AIIMS, New Delhi – **NEW**
- Post Graduate Institute, PGI Chandigarh – **NEW**
- Tata Medical Centre, Kolkata - **NEW**

### INPHOG-SUPP-22-03

**Anti-Emetic Prophylaxis for Chemotherapy-Induced Vomiting Without Dexamethasone for Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Open-Label, Multi-Center, Non-Inferiority, Phase III Randomized Controlled Trial**

<b>Principal Investigator</b>	Dr Venkatraman Radhakrishnan
<b>Registered with INPHOG</b>	June 2022
<b>CTRI Registration</b>	CTRI/2022/08/045009
<b>Recruitment commenced</b>	No
<b>Currently patients recruited</b>	68
<b>Target patient recruitment</b>	300

**Anticipated duration of recruitment** 3 years  
**Centers study open in** 03

- JIPMER, Puducherry – **NEW**
- AIIMS, New Delhi – **NEW**
- Cancer Institute, Chennai – **NEW**

**INPHOG-GCT-22-01**

**Integrated Clinico-pathological and treatment outcome analysis of extra-cranial malignant germ cell tumors in children and adolescents in India.**

**Principal Investigator** Dr Sonali Mohapatra  
**Registered with INPHOG** March 2023  
**CTRI Registration** Pending  
**Recruitment commenced** Yes  
**Currently patients recruited** 22  
**Target patient recruitment** 300-400  
**Anticipated duration of recruitment** 18 Months  
**Centers study open in** 06

- Rainbow Children's Hospital, Hyderabad – **NEW**
- Indraprastha Apollo Hospitals, New Delhi – **NEW**
- SKIMs, Jammu and Kashmir – **NEW**
- Dayanand Medical College & Hospital, Ludhiana – **NEW**
- AIIMS Bhuvneshwar – **NEW**
- MVR Cancer Centre, Kozhikode – **NEW**

**INPHOG-EPI-22-03**

**Establishing the first dedicated Population-Based Childhood Cancer Registry (PBCCR) And network of Hospital-Based Childhood Cancer Registries (HBCCRs) in India.**

**Principal Investigator** Dr Venkatraman Radhakrishnan  
**Registered with INPHOG** Sep 2022  
**CTRI Registration** CTRI/2022/06/043526  
**Recruitment commenced** Sep 2022  
**Currently patients recruited** 166  
**Target patient recruitment** 1000  
**Anticipated duration of recruitment** Continuous

**Centers study open in**

12

- Rajiv Gandhi Government Hospital, Chennai – **NEW**
- Royapettah government Hospital, Chennai – **NEW**
- ICH Government Hospital, Chennai – **NEW**
- Tamil Nadu Multispecialty Hospital, Chennai – **NEW**
- Apollo Specialty Hospital (cancer center), Chennai – **NEW**
- Rainbow children Hospital – **NEW**
- Dr. Mehta’s Hospital, Chennai – **NEW**
- Sankara Nethralaya Eye Hospital, Chennai – **NEW**
- Kauvery Hospital, Chennai – **NEW**
- Cancer Institute (WIA), Adyar – **NEW**
- Dr. Rela Hospital, Chennai – **NEW**
- Global Hospital, Chennai – **NEW**

**INPHOG-AML-23-02**

**Indian Childhood Acute Promyelocytic Leukemia Study (I-CHAMPs)**

<b>Principal Investigator</b>	Dr Smita Kayal
<b>Registered with INPHOG</b>	March 2023
<b>CTRI Registration</b>	REF/2023/08/071948
<b>Recruitment commenced</b>	Yet to start
<b>Currently patients recruited</b>	0
<b>Target patient recruitment</b>	100-200 Annually
<b>Anticipated duration of recruitment</b>	Retrospective Registry (1 year)/ Prospective Registry (5 years)
<b>Centers study open in</b>	02

- JIPMER, Puducherry – **NEW**
- AIIMS, New Delhi – **NEW**

# INPHOG Studies Granted Full Registration (1)

---

## **InPOG-NB-18-02**

### **Indian Non-high Risk Neuroblastoma Study**

<b>Principal Investigator</b>	Dr Vikramjit Kanwar
<b>Registered with INPHOG</b>	Sep 2020
<b>CTRI Registration</b>	
<b>Recruitment commenced</b>	No
<b>Currently patients recruited</b>	NA
<b>Target patient recruitment</b>	Not specified
<b>Anticipated duration of recruitment</b>	Not specified
<b>Centers study open in</b>	No

## INPHOG Studies Granted Provisional Registration (3)

---

**InPOG-SCT-20-02 (P)** A multicenter collaborative study for evaluating the outcome in children with high-risk neuroblastoma undergoing autologous stem cell transplantation (NBL-ASCT). **PI - Venkateswaran V S**

**INPHOG-RBC-22-01 (P)** A Cross-sectional study of children receiving regular red cell transfusions for primary non-malignant hematological conditions excluding thalassemia and sickle cell anemia– Assessment of disease burden and clinical profile. **PI - Stalin Ramprakash**

**INPHOG-SUPP-23-04 (P)** Drug induced Diabetes Mellitus management in children with Acute Leukemia (ALL) – A Phase-2 Open-Label Randomized Control Trial (RCT) comparing two treatment arms (Insulin alone Vs Insulin + Metformin) **Dr. Kalasekhar V.S – NEW**